Furthermore, NF-κB-activating genes were induced in RASFsn-stimulated chondrocytes, including RIPK2, TLR2, the NF-κB-associated genes NF-κB1 and NF-κB2, and SMS. Promoters of numerous genes involved in inflammation and MMP expression show NF-κB-binding sites [45-47]; NF-κB-dependent genes may therefore be prominent drug targets in RA therapy. This evidence concerns the gene NFKB2 and rheumatoid arthritis.